China Reviews Essential Drug Pricing Model After GMP Violations From Multi-bid Winner
This article was originally published in The Pink Sheet Daily
Industry questions whether the program is purely price competition at the expense of quality.
You may also be interested in...
In China, A Province's Drastic Price Cut Model Is Being Modified To Fit A Nationwide System: A Look At The Anhui Model
SHANGHAI - Since China's healthcare reforms started in 2009, the central government has been encouraging local government to pilot different tender models for essential drugs to reduce public medical expenses. Anhui Province's tender system became a successful example by reducing essential drug prices an average 40-50% last year, and now the central government is implementing a single supplier procurement system, the so-called Anhui model, nationwide
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.